NYSE:MD - MEDNAX Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$46.87 +0.09 (+0.19 %)
(As of 05/24/2018 06:00 AM ET)
Previous Close$46.87
Today's Range$46.44 - $46.91
52-Week Range$40.56 - $63.04
Volume236,900 shs
Average Volume1.00 million shs
Market Capitalization$4.42 billion
P/E Ratio14.39
Dividend YieldN/A
Beta0.26

About MEDNAX (NYSE:MD)

MEDNAX logoMEDNAX, Inc., together with its subsidiaries, provides newborn, anesthesia, maternal-fetal, radiology, pediatric cardiology, and other pediatric subspecialties physician services in the United States and Puerto Rico. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians; anesthesia and anesthesia subspecialty care; and acute and chronic pain management services. The company also provides maternal-fetal care, including inpatient and office-based clinical care to expectant mothers and their unborn babies through maternal-fetal medicine subspecialists, as well as obstetricians and other clinicians consisting of maternal-fetal nurse practitioners, certified nurse mid-wives, ultrasonographers, and genetic counselors. In addition, its pediatric cardiology care services comprise inpatient and office-based pediatric cardiology care of the fetus, infant, child, and adolescent patient with congenital heart defects and acquired heart disease, as well as adults with congenital heart defects through pediatric cardiologist subspecialists and other related clinical professionals. Further, the company provides other pediatric subspecialty care services through pediatric subspecialists, such as pediatric intensivists, pediatric hospitalists, and pediatric surgeons, as well as pediatric ear, nose, and throat physicians; and support services in the areas of hospitals, primarily in the pediatric emergency rooms, labor and delivery areas, and nursery and pediatric departments. Additionally, it provides radiology and teleradiology services. As of December 31, 2017, the company's network consisted of approximately 4,075 affiliated physicians. MEDNAX, Inc. was founded in 1979 and is based in Sunrise, Florida.

Receive MD News and Ratings via Email

Sign-up to receive the latest news and ratings for MD and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Hospitals
Sub-IndustryHealth Care Services
SectorMedical
SymbolNYSE:MD
CUSIP58502B10
Phone954-384-0175

Debt

Debt-to-Equity Ratio0.63
Current Ratio1.74
Quick Ratio1.74

Price-To-Earnings

Trailing P/E Ratio14.39
Forward P/E Ratio11.87
P/E Growth1.18

Sales & Book Value

Annual Sales$3.46 billion
Price / Sales1.28
Cash Flow$4.2882 per share
Price / Cash10.93
Book Value$33.31 per share
Price / Book1.41

Profitability

EPS (Most Recent Fiscal Year)$3.15
Net Income$320.37 million
Net Margins9.34%
Return on Equity10.13%
Return on Assets5.31%

Miscellaneous

Employees7,675
Outstanding Shares94,380,000

MEDNAX (NYSE:MD) Frequently Asked Questions

What is MEDNAX's stock symbol?

MEDNAX trades on the New York Stock Exchange (NYSE) under the ticker symbol "MD."

How were MEDNAX's earnings last quarter?

MEDNAX Inc (NYSE:MD) announced its quarterly earnings results on Monday, April, 30th. The company reported $0.89 EPS for the quarter, topping the consensus estimate of $0.82 by $0.07. The business had revenue of $901.90 million for the quarter, compared to analysts' expectations of $903.75 million. MEDNAX had a net margin of 9.34% and a return on equity of 10.13%. The business's quarterly revenue was up 7.9% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.75 EPS. View MEDNAX's Earnings History.

When is MEDNAX's next earnings date?

MEDNAX is scheduled to release their next quarterly earnings announcement on Thursday, July, 26th 2018. View Earnings Estimates for MEDNAX.

What guidance has MEDNAX issued on next quarter's earnings?

MEDNAX updated its second quarter earnings guidance on Monday, April, 30th. The company provided earnings per share guidance of $1.04-1.09 for the period, compared to the Thomson Reuters consensus EPS estimate of $1.07.

What price target have analysts set for MD?

12 brokerages have issued 12-month price targets for MEDNAX's stock. Their predictions range from $50.00 to $62.00. On average, they anticipate MEDNAX's share price to reach $55.5833 in the next year. View Analyst Ratings for MEDNAX.

Who are some of MEDNAX's key competitors?

Who are MEDNAX's key executives?

MEDNAX's management team includes the folowing people:
  • Dr. Roger J. Medel, Co-Founder, CEO & Director (Age 71)
  • Mr. Joseph M. Calabro, Pres & COO (Age 57)
  • Ms. Vivian Lopez-Blanco, CFO & Treasurer (Age 60)
  • Mr. Dominic J. Andreano, Sr. VP, Gen. Counsel & Sec. (Age 49)
  • Mr. David A. Clark, Pres of Mednax National Medical Group Division (Age 51)

Has MEDNAX been receiving favorable news coverage?

News headlines about MD stock have been trending somewhat positive this week, Accern Sentiment Analysis reports. The research group identifies positive and negative news coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. MEDNAX earned a news sentiment score of 0.06 on Accern's scale. They also gave news coverage about the company an impact score of 46.61 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company's share price in the next few days.

Who are MEDNAX's major shareholders?

MEDNAX's stock is owned by many different of retail and institutional investors. Top institutional investors include BlackRock Inc. (8.34%), Blue Harbour Group L.P. (4.77%), Pzena Investment Management LLC (2.41%), Earnest Partners LLC (2.22%), Dimensional Fund Advisors LP (2.18%) and Wedge Capital Management L L P NC (2.09%). Company insiders that own MEDNAX stock include Cesar L Alvarez, Dominic J Andreano, Enrique Sosa, John C Pepia, Joseph M Calabro, Karl B Wagner, Manuel Kadre, Md Carlo A Waldemar, Md Pascal J Goldschmidt, Michael D Stanley, Paul G Gabos, Robert Irwin Valliant and Vivian Lopez-Blanco. View Institutional Ownership Trends for MEDNAX.

Which major investors are selling MEDNAX stock?

MD stock was sold by a variety of institutional investors in the last quarter, including Massachusetts Financial Services Co. MA, Thompson Siegel & Walmsley LLC, Cooke & Bieler LP, Flinton Capital Management LLC, Toronto Dominion Bank, Hsbc Holdings PLC, Tyers Asset Management LLC and Tiverton Asset Management LLC. Company insiders that have sold MEDNAX company stock in the last year include Cesar L Alvarez, John C Pepia, Joseph M Calabro and Md Pascal J Goldschmidt. View Insider Buying and Selling for MEDNAX.

Which major investors are buying MEDNAX stock?

MD stock was bought by a variety of institutional investors in the last quarter, including Pzena Investment Management LLC, MUFG Securities EMEA plc, BNP Paribas Arbitrage SA, Blue Harbour Group L.P., Dimensional Fund Advisors LP, Millennium Management LLC, Prudential Financial Inc. and FIL Ltd. Company insiders that have bought MEDNAX stock in the last two years include Manuel Kadre and Md Pascal J Goldschmidt. View Insider Buying and Selling for MEDNAX.

How do I buy shares of MEDNAX?

Shares of MD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is MEDNAX's stock price today?

One share of MD stock can currently be purchased for approximately $46.87.

How big of a company is MEDNAX?

MEDNAX has a market capitalization of $4.40 billion and generates $3.46 billion in revenue each year. The company earns $320.37 million in net income (profit) each year or $3.15 on an earnings per share basis. MEDNAX employs 7,675 workers across the globe.

How can I contact MEDNAX?

MEDNAX's mailing address is 1301 CONCORD TERRACE, SUNRISE FL, 33323. The company can be reached via phone at 954-384-0175 or via email at [email protected]


MarketBeat Community Rating for MEDNAX (MD)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  346 (Vote Outperform)
Underperform Votes:  376 (Vote Underperform)
Total Votes:  722
MarketBeat's community ratings are surveys of what our community members think about MEDNAX and other stocks. Vote "Outperform" if you believe MD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MD will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

MEDNAX (NYSE:MD) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
12 Wall Street analysts have issued ratings and price targets for MEDNAX in the last 12 months. Their average twelve-month price target is $55.5833, suggesting that the stock has a possible upside of 18.59%. The high price target for MD is $62.00 and the low price target for MD is $50.00. There are currently 9 hold ratings and 3 buy ratings for the stock, resulting in a consensus rating of "Hold."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldHoldHold
Consensus Rating Score: 2.252.152.172.09
Ratings Breakdown: 0 Sell Rating(s)
9 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
9 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
8 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
8 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $55.5833$55.3333$54.4545$54.50
Price Target Upside: 18.59% upside0.50% upside0.95% upside25.66% upside

MEDNAX (NYSE:MD) Consensus Price Target History

Price Target History for MEDNAX (NYSE:MD)

MEDNAX (NYSE:MD) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/7/2018Credit Suisse GroupLower Price TargetNeutral ➝ Neutral$57.00LowView Rating Details
5/4/2018CitigroupLower Price TargetNeutral ➝ Neutral$57.00 ➝ $50.00LowView Rating Details
3/15/2018Jefferies GroupSet Price TargetHold$58.00LowView Rating Details
2/12/2018BMO Capital MarketsBoost Price TargetMarket Perform ➝ Market Perform$46.00 ➝ $58.00LowView Rating Details
2/12/2018JPMorgan Chase & Co.Boost Price TargetNeutral ➝ Neutral$46.00 ➝ $55.00LowView Rating Details
2/9/2018MizuhoReiterated RatingNeutral ➝ Neutral$49.00 ➝ $53.00LowView Rating Details
2/9/2018Robert W. BairdBoost Price TargetNeutral ➝ Neutral$48.00 ➝ $54.00MediumView Rating Details
2/8/2018StephensSet Price TargetBuy$62.00MediumView Rating Details
1/24/2018Stifel NicolausReiterated RatingHold$56.00LowView Rating Details
12/21/2017SunTrust BanksSet Price TargetHold$55.00MediumView Rating Details
12/13/2017Piper Jaffray CompaniesInitiated CoverageOverweight ➝ Overweight$58.00LowView Rating Details
11/1/2017KeyCorpSet Price TargetBuy$51.00N/AView Rating Details
5/4/2017Bank of AmericaDowngradeBuy ➝ UnderperformLowView Rating Details
12/9/2016Goldman Sachs GroupInitiated CoverageNeutral$66.00N/AView Rating Details
10/27/2016Raymond JamesDowngradeOutperform ➝ Market PerformN/AView Rating Details
10/27/2016UBSDowngradeOutperform ➝ Market PerformN/AView Rating Details
(Data available from 5/24/2016 forward)

Earnings

MEDNAX (NYSE:MD) Earnings History and Estimates Chart

Earnings by Quarter for MEDNAX (NYSE:MD)

MEDNAX (NYSE:MD) Earnings Estimates

2018 EPS Consensus Estimate: $3.90
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20182$0.78$0.80$0.79
Q2 20183$0.97$1.01$0.99
Q3 20183$1.03$1.09$1.06
Q4 20183$1.03$1.09$1.06

MEDNAX (NYSE MD) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
7/26/2018$1.06N/AView Earnings Details
4/30/2018Q1 2018$0.82$0.89$903.75 million$901.90 millionViewN/AView Earnings Details
2/8/2018Q4 2017$0.8330$0.87$884.55 million$910.82 millionViewN/AView Earnings Details
11/1/2017Q3 2017$0.87$0.87$864.78 million$868.95 millionViewN/AView Earnings Details
7/28/2017Q2 2017$0.81$0.85$849.49 million$843.00 millionViewN/AView Earnings Details
5/4/2017Q1 2017$0.7440$0.75$837.01 million$835.60 millionViewN/AView Earnings Details
4/20/2017Q1 2017$0.81$0.70$839.25 million$836.00 millionViewN/AView Earnings Details
2/7/2017Q416$1.06$1.00$842.15 million$831.00 millionViewListenView Earnings Details
10/27/2016Q316$1.05$1.09$821.18 million$828.00 millionViewListenView Earnings Details
7/28/2016Q216$1.07$1.03$775.68 million$772.00 millionViewListenView Earnings Details
4/28/2016Q116$0.86$0.87$741.49 million$752.60 millionViewListenView Earnings Details
2/4/2016Q415$1.10$1.13$748.02 million$742.00 millionViewListenView Earnings Details
10/29/2015Q315$0.97$1.10$730.63 million$722.30 millionViewListenView Earnings Details
7/30/2015Q215$0.88$0.97$677.02 million$676.60 millionViewListenView Earnings Details
4/30/2015Q115$0.71$0.72$641.24 million$639.40 millionViewListenView Earnings Details
1/29/2015Q414$0.87$0.89$637.90 million$651.00 millionViewListenView Earnings Details
10/30/2014Q314$0.85$0.86$619.61 million$627.00 millionViewListenView Earnings Details
7/31/2014Q214$0.78$0.79$603.00 million$595.54 millionViewListenView Earnings Details
5/1/2014Q114$0.63$0.63$574.80 million$566.00 millionViewListenView Earnings Details
1/30/2014Q4$0.75$0.20$555.30 million$567.00 millionViewListenView Earnings Details
10/31/2013Q313$1.48$1.52$556.63 million$555.00 millionViewListenView Earnings Details
7/30/2013Q2 2013$1.36$1.37$533.39 million$529.18 millionViewListenView Earnings Details
5/2/2013Q1 2013$1.09$1.10$504.24 million$502.70 millionViewListenView Earnings Details
1/31/2013Q4 2012$1.30$1.32$473.70 million$471.30 millionViewListenView Earnings Details
11/1/2012Q312$1.28$1.32$470.60 million$473.10 millionViewN/AView Earnings Details
7/31/2012$1.19$1.22ViewN/AView Earnings Details
5/3/2012$1.00$0.98ViewN/AView Earnings Details
2/2/2012$1.19$1.19ViewN/AView Earnings Details
11/1/2011$1.18$1.19ViewN/AView Earnings Details
8/2/2011$1.15$1.15ViewN/AView Earnings Details
5/3/2011$0.91$0.94ViewN/AView Earnings Details
2/3/2011$1.12$1.12ViewN/AView Earnings Details
11/2/2010Q3 2010$0.53$0.53ViewN/AView Earnings Details
8/3/2010Q2 2010$0.51$0.52ViewN/AView Earnings Details
5/3/2010Q1 2010$0.41$0.41ViewN/AView Earnings Details
2/5/2010Q4 2009$0.49$0.50ViewN/AView Earnings Details
11/2/2009Q3 2009$0.48$0.52ViewN/AView Earnings Details
8/4/2009Q2 2009$0.43$0.47ViewN/AView Earnings Details
5/7/2009Q1 2009$0.33$0.37ViewN/AView Earnings Details
2/5/2009Q4 2008$0.39$0.41ViewN/AView Earnings Details
11/5/2008Q3 2008$0.41$0.41ViewN/AView Earnings Details
8/5/2008Q2 2008$0.39$0.40ViewN/AView Earnings Details
5/8/2008Q1 2008$0.34$0.33ViewN/AView Earnings Details
2/6/2008Q4 2007$0.40$0.40ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

MEDNAX (NYSE:MD) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

MEDNAX (NYSE MD) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 2.40%
Institutional Ownership Percentage: 97.14%
Insider Trading History for MEDNAX (NYSE:MD)
Institutional Ownership by Quarter for MEDNAX (NYSE:MD)

MEDNAX (NYSE MD) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
5/22/2018John C PepiaInsiderSell3,000$46.43$139,290.0039,716View SEC Filing  
3/13/2018John C PepiaInsiderSell3,000$58.35$175,050.0039,716View SEC Filing  
12/12/2017John C PepiaInsiderSell3,000$51.58$154,740.0035,569View SEC Filing  
11/3/2017Cesar L AlvarezDirectorSell10,668$42.59$454,350.1244,215View SEC Filing  
9/12/2017John C PepiaInsiderSell3,000$42.85$128,550.0035,569View SEC Filing  
6/14/2017Md Pascal J GoldschmidtDirectorSell1,969$57.57$113,355.3318,072View SEC Filing  
6/1/2017Joseph M CalabroInsiderSell23,327$55.00$1,282,985.00296,379View SEC Filing  
5/5/2017Manuel KadreDirectorBuy21,704$55.79$1,210,866.16111,255View SEC Filing  
5/5/2017Vivian Lopez-BlancoCFOSell7,778$55.82$434,167.9651,319View SEC Filing  
3/16/2017Robert Irwin ValliantDirectorSell5,200$1.10$5,720.00
2/23/2017Enrique SosaDirectorSell10,668$69.65$743,026.2021,923View SEC Filing  
2/17/2017Vivian Lopez-BlancoCFOSell15,164$70.01$1,061,631.6459,097View SEC Filing  
2/16/2017Dominic J AndreanoSVPSell6,000$69.59$417,540.0030,746View SEC Filing  
2/16/2017John C PepiaInsiderSell2,500$69.58$173,950.0031,025View SEC Filing  
2/16/2017Paul G GabosDirectorSell21,336$69.63$1,485,625.6821,923View SEC Filing  
2/10/2017Md Pascal J GoldschmidtDirectorSell25,294$67.82$1,715,439.0814,173View SEC Filing  
2/9/2017Md Carlo A WaldemarDirectorSell5,334$67.90$362,178.6016,589View SEC Filing  
1/17/2017Vivian Lopez-BlancoCFOSell10,000$70.95$709,500.0074,261View SEC Filing  
12/7/2016Md Pascal J GoldschmidtDirectorBuy2,100$66.52$139,692.0013,355View SEC Filing  
9/14/2016Md Pascal J GoldschmidtDirectorSell1,500$65.01$97,515.0012,755View SEC Filing  
6/13/2016Dominic J AndreanoSVPSell3,922$68.80$269,833.6024,746View SEC Filing  
6/8/2016Md Carlo A WaldemarDirectorSell5,334$70.50$376,047.0016,589View SEC Filing  
6/7/2016Karl B WagnerInsiderSell27,482$68.45$1,881,142.90105,932View SEC Filing  
6/1/2016Joseph M CalabroCOOSell28,347$67.78$1,921,359.66253,882View SEC Filing  
6/1/2016Michael D StanleyInsiderSell14,778$67.78$1,001,652.8449,266View SEC Filing  
5/16/2016Dominic J AndreanoSVPSell3,000$68.53$205,590.0021,313View SEC Filing  
5/2/2016Vivian Lopez-BlancoCFOSell9,350$71.22$665,907.0064,083View SEC Filing  
3/11/2016Md Pascal J GoldschmidtDirectorSell3,100$65.00$201,500.0012,479View SEC Filing  
2/29/2016Paul G GabosDirectorSell10,668$67.15$716,356.2020,047View SEC Filing  
12/11/2015Md Pascal J. GoldschmidtDirectorSell5,250$70.99$372,697.509,379View SEC Filing  
9/8/2015Cesar L. AlvarezDirectorSell10,668$81.00$864,108.0029,379View SEC Filing  
8/27/2015Roger Md MedelCEOSell100,000$80.27$8,027,000.001,199,708View SEC Filing  
6/8/2015Karl B WagnerInsiderSell37,820$70.28$2,657,989.60View SEC Filing  
6/3/2015Joseph M CalabroCOOSell108,071$70.51$7,620,086.21View SEC Filing  
3/9/2015Md Pascal J GoldschmidtDirectorSell8,500$71.25$605,625.00View SEC Filing  
2/26/2015Roger Md MedelCEOSell100,000$71.61$7,161,000.00View SEC Filing  
2/20/2015Md Carlo A WaldemarDirectorSell10,668$71.50$762,762.00View SEC Filing  
2/6/2015Dominic J AndreanoSVPSell3,200$70.75$226,400.00View SEC Filing  
2/6/2015Vivian Lopez-BlancoCFOSell8,250$69.95$577,087.50View SEC Filing  
2/2/2015Paul G GabosDirectorSell17,584$68.07$1,196,942.88View SEC Filing  
1/30/2015William C HawkCOOSell3,598$68.50$246,463.00View SEC Filing  
11/14/2014Roger Md MedelCEOSell51,290$62.59$3,210,241.10View SEC Filing  
11/13/2014Roger Md MedelCEOSell63,440$62.55$3,968,172.00View SEC Filing  
11/7/2014Roger Md MedelCEOSell128,833$62.60$8,064,945.80View SEC Filing  
11/5/2014Roger Md MedelCEOSell169,845$62.60$10,632,297.00View SEC Filing  
11/4/2014Roger Md MedelCEOSell15,052$62.52$941,051.04View SEC Filing  
11/3/2014Roger Md MedelCEOSell10,881$62.52$680,280.12View SEC Filing  
10/31/2014Roger Md MedelCEOSell61,592$62.58$3,854,427.36View SEC Filing  
10/30/2014Karl B WagnerInsiderSell40,000$62.50$2,500,000.00View SEC Filing  
10/30/2014Vivian Lopez-BlancoCFOSell8,800$60.00$528,000.00View SEC Filing  
7/30/2014Karl B WagnerInsiderSell80,000$60.00$4,800,000.00View SEC Filing  
6/10/2014Dominic J AndreanoSVPSell2,252$58.48$131,696.96View SEC Filing  
6/6/2014Karl B WagnerInsiderSell44,596$58.53$2,610,203.88View SEC Filing  
6/5/2014William C HawkCOOSell6,911$57.66$398,488.26View SEC Filing  
6/2/2014David A ClarkCOOSell16,230$57.00$925,110.00View SEC Filing  
6/2/2014Michael D StanleyInsiderSell18,006$57.00$1,026,342.00View SEC Filing  
5/9/2014Karl WagnerInsiderSell79,524$57.09$4,540,025.16150,498View SEC Filing  
5/9/2014Md Pascal GoldschmidtDirectorSell30,000$57.11$1,713,300.005,350View SEC Filing  
5/8/2014Joseph CalabroCOOSell137,500$57.06$7,845,750.00226,542View SEC Filing  
2/20/2014Dominic AndreanoSVPSell3,000$61.00$183,000.0016,135View SEC Filing  
2/10/2014Joseph CalabroCOOSell150,000$55.55$8,332,500.00226,542View SEC Filing  
2/10/2014Md Carlo WaldemarDirectorSell10,668$55.40$591,007.205,350View SEC Filing  
11/7/2013Enrique SosaDirectorSell5,334$107.00$570,738.002,675View SEC Filing  
11/7/2013Karl WagnerInsiderSell1,800$107.60$193,680.0075,249View SEC Filing  
9/11/2013William C HawkCOOSell3,162$100.62$318,160.44View SEC Filing  
9/10/2013Dominic J AndreanoSVPSell3,718$99.63$370,424.34View SEC Filing  
8/7/2013Karl WagnerInsiderSell25,000$98.01$2,450,250.0075,249View SEC Filing  
8/2/2013Joseph M CalabroCOOSell36,154$98.57$3,563,699.78View SEC Filing  
6/3/2013David A ClarkCOOSell8,645$91.01$786,781.45View SEC Filing  
6/3/2013Michael D StanleyInsiderSell8,906$91.01$810,535.06View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

MEDNAX (NYSE MD) News Headlines

Source:
DateHeadline
Insider Selling: MEDNAX Inc (MD) Insider Sells 3,000 Shares of StockInsider Selling: MEDNAX Inc (MD) Insider Sells 3,000 Shares of Stock
www.americanbankingnews.com - May 23 at 7:52 PM
Interesting MD Put And Call Options For July 20thInteresting MD Put And Call Options For July 20th
www.nasdaq.com - May 21 at 4:08 PM
$911.91 Million in Sales Expected for MEDNAX Inc (MD) This Quarter$911.91 Million in Sales Expected for MEDNAX Inc (MD) This Quarter
www.americanbankingnews.com - May 21 at 4:40 AM
Mednax (MD) Expected to Announce Earnings of $1.06 Per ShareMednax (MD) Expected to Announce Earnings of $1.06 Per Share
www.americanbankingnews.com - May 19 at 5:59 AM
Judge denies temporary restraining order in Atrium-Southeast Anesthesiology contract dispute, sets hearingJudge denies temporary restraining order in Atrium-Southeast Anesthesiology contract dispute, sets hearing
finance.yahoo.com - May 16 at 4:06 PM
Southeast Anesthesiology seeks temporary restraining order against Atrium Health as contract dispute escalatesSoutheast Anesthesiology seeks temporary restraining order against Atrium Health as contract dispute escalates
finance.yahoo.com - May 14 at 4:06 PM
Mednax (MD) Given Average Rating of "Hold" by AnalystsMednax (MD) Given Average Rating of "Hold" by Analysts
www.americanbankingnews.com - May 13 at 1:59 PM
MEDNAX, Inc (MD) CEO Roger Medel on Q1 2018 Results - Earnings Call TranscriptMEDNAX, Inc (MD) CEO Roger Medel on Q1 2018 Results - Earnings Call Transcript
seekingalpha.com - May 8 at 9:46 AM
Atrium Health Amends Countersuit to Mednax Due to Continued False Fear-based Ad CampaignAtrium Health Amends Countersuit to Mednax Due to Continued False Fear-based Ad Campaign
finance.yahoo.com - May 8 at 9:46 AM
Atrium updates lawsuit, says fear-based campaign set to ‘poison public mindset’Atrium updates lawsuit, says fear-based campaign set to ‘poison public mindset’
www.bizjournals.com - May 7 at 4:13 PM
Mednax (MD) Price Target Lowered to $47.00 at Credit Suisse GroupMednax (MD) Price Target Lowered to $47.00 at Credit Suisse Group
www.americanbankingnews.com - May 7 at 11:02 AM
Mednax (MD) Upgraded at Zacks Investment ResearchMednax (MD) Upgraded at Zacks Investment Research
www.americanbankingnews.com - May 5 at 6:37 AM
Citigroup Lowers Mednax (MD) Price Target to $50.00Citigroup Lowers Mednax (MD) Price Target to $50.00
www.americanbankingnews.com - May 5 at 2:59 AM
Mednax (MD) Expected to Earn Q2 2018 Earnings of $1.01 Per ShareMednax (MD) Expected to Earn Q2 2018 Earnings of $1.01 Per Share
www.americanbankingnews.com - May 4 at 7:36 AM
Brokers Offer Predictions for Mednaxs Q2 2018 Earnings (MD)Brokers Offer Predictions for Mednax's Q2 2018 Earnings (MD)
www.americanbankingnews.com - May 4 at 7:36 AM
$911.05 Million in Sales Expected for Mednax (MD) This Quarter$911.05 Million in Sales Expected for Mednax (MD) This Quarter
www.americanbankingnews.com - May 3 at 2:48 AM
Mednax (MD) Stock Rating Lowered by ValuEngineMednax (MD) Stock Rating Lowered by ValuEngine
www.americanbankingnews.com - May 3 at 12:10 AM
Encompass Health (EHC) versus Mednax (MD) Critical AnalysisEncompass Health (EHC) versus Mednax (MD) Critical Analysis
www.americanbankingnews.com - May 2 at 5:44 PM
Off Wall Street closes short on Mednax; shares up 3.2%Off Wall Street closes short on Mednax; shares up 3.2%
seekingalpha.com - May 2 at 2:13 PM
Edited Transcript of MD earnings conference call or presentation 1-May-18 1:00pm GMTEdited Transcript of MD earnings conference call or presentation 1-May-18 1:00pm GMT
finance.yahoo.com - May 2 at 9:47 AM
Mednax (MD) Expected to Post Earnings of $1.08 Per ShareMednax (MD) Expected to Post Earnings of $1.08 Per Share
www.americanbankingnews.com - May 1 at 5:08 PM
Mednax (MD) Announces  Earnings ResultsMednax (MD) Announces Earnings Results
www.americanbankingnews.com - May 1 at 12:04 PM
Mednax: 1Q Earnings SnapshotMednax: 1Q Earnings Snapshot
finance.yahoo.com - May 1 at 9:52 AM
Mednax (MD) Releases Q2 Earnings GuidanceMednax (MD) Releases Q2 Earnings Guidance
www.americanbankingnews.com - April 30 at 9:16 PM
Mednax (MD) and Magellan Health (MGLN) Head to Head AnalysisMednax (MD) and Magellan Health (MGLN) Head to Head Analysis
www.americanbankingnews.com - April 30 at 1:39 PM
Traders Buy Large Volume of Mednax Put Options (MD)Traders Buy Large Volume of Mednax Put Options (MD)
www.americanbankingnews.com - April 27 at 8:08 AM
Pre-Open Movers 04/26: (CRK) (MATR) (CMG) (AMD) Higher; (SPB) (FARO) (MD) (T) Lower (more...)Pre-Open Movers 04/26: (CRK) (MATR) (CMG) (AMD) Higher; (SPB) (FARO) (MD) (T) Lower (more...)
www.streetinsider.com - April 26 at 4:08 PM
Short-seller Jim Chanos bets against two health-care companies: They 'might be worth nothing'Short-seller Jim Chanos bets against two health-care companies: They 'might be worth nothing'
finance.yahoo.com - April 26 at 9:39 AM
Atrium CEO: Anesthesiology practice using ‘fear-based’ campaignAtrium CEO: Anesthesiology practice using ‘fear-based’ campaign
finance.yahoo.com - April 26 at 9:39 AM
Mednax (MD) Downgraded by TheStreetMednax (MD) Downgraded by TheStreet
www.americanbankingnews.com - April 25 at 10:25 AM
Mednax (MD) Set to Announce Earnings on WednesdayMednax (MD) Set to Announce Earnings on Wednesday
www.americanbankingnews.com - April 25 at 3:16 AM
MEDNAX (MD) Reports Acquisition of Womens Radiology Associates LLP in Houston, TXMEDNAX (MD) Reports Acquisition of Women's Radiology Associates LLP in Houston, TX
www.streetinsider.com - April 24 at 9:50 AM
Magellan Health (MGLN) & Mednax (MD) Critical ContrastMagellan Health (MGLN) & Mednax (MD) Critical Contrast
www.americanbankingnews.com - April 22 at 9:14 PM
MEDNAX 2018 First Quarter Conference Call/Webcast Scheduled for Monday, May 7, 2018MEDNAX 2018 First Quarter Conference Call/Webcast Scheduled for Monday, May 7, 2018
finance.yahoo.com - April 20 at 4:10 PM
THE LIST: Legal battles shaking up Charlotte’s largest physician groupsTHE LIST: Legal battles shaking up Charlotte’s largest physician groups
finance.yahoo.com - April 20 at 10:08 AM
Comparing MEDNAX (MD) and Encompass Health (EHC)Comparing MEDNAX (MD) and Encompass Health (EHC)
www.americanbankingnews.com - April 19 at 9:42 AM
MedTech Stocks Q1 Earnings: Key Predictions for DGX, MD, CHEMedTech Stocks Q1 Earnings: Key Predictions for DGX, MD, CHE
finance.yahoo.com - April 18 at 4:18 PM
MEDNAX Inc (MD) Receives Average Rating of "Hold" from AnalystsMEDNAX Inc (MD) Receives Average Rating of "Hold" from Analysts
www.americanbankingnews.com - April 18 at 1:34 PM
Head-To-Head Comparison: MEDNAX (MD) vs. Magellan Health (MGLN)Head-To-Head Comparison: MEDNAX (MD) vs. Magellan Health (MGLN)
www.americanbankingnews.com - April 18 at 3:20 AM
$904.13 Million in Sales Expected for MEDNAX Inc (MD) This Quarter$904.13 Million in Sales Expected for MEDNAX Inc (MD) This Quarter
www.americanbankingnews.com - April 16 at 2:37 AM
MEDNAX (MD) and Magellan Health (MGLN) Critical SurveyMEDNAX (MD) and Magellan Health (MGLN) Critical Survey
www.americanbankingnews.com - April 15 at 11:15 AM
MEDNAX (MD) Given a $46.00 Price Target at Jefferies GroupMEDNAX (MD) Given a $46.00 Price Target at Jefferies Group
www.americanbankingnews.com - April 15 at 9:45 AM
Zacks: Brokerages Anticipate MEDNAX Inc (MD) Will Post Earnings of $0.85 Per ShareZacks: Brokerages Anticipate MEDNAX Inc (MD) Will Post Earnings of $0.85 Per Share
www.americanbankingnews.com - April 14 at 5:09 PM
Analyzing Encompass Health (EHC) & MEDNAX (MD)Analyzing Encompass Health (EHC) & MEDNAX (MD)
www.americanbankingnews.com - April 13 at 1:07 AM
Edited Transcript of MD presentation 6-Mar-17 1:40pm GMTEdited Transcript of MD presentation 6-Mar-17 1:40pm GMT
finance.yahoo.com - April 12 at 10:52 AM
MEDNAX (MD) Rating Lowered to Sell at Zacks Investment ResearchMEDNAX (MD) Rating Lowered to Sell at Zacks Investment Research
www.americanbankingnews.com - April 11 at 8:58 AM
MedData’s New Patient Financial Platform Solves Inefficient, Costly Revenue Cycle ChallengesMedData’s New Patient Financial Platform Solves Inefficient, Costly Revenue Cycle Challenges
finance.yahoo.com - April 10 at 10:20 AM
Financial Contrast: Encompass Health (EHC) & MEDNAX (MD)Financial Contrast: Encompass Health (EHC) & MEDNAX (MD)
www.americanbankingnews.com - April 10 at 5:29 AM
Analyzing MEDNAX (MD) and Magellan Health (MGLN)Analyzing MEDNAX (MD) and Magellan Health (MGLN)
www.americanbankingnews.com - April 8 at 1:27 PM
MEDNAX (MD) Rating Increased to Hold at Zacks Investment ResearchMEDNAX (MD) Rating Increased to Hold at Zacks Investment Research
www.americanbankingnews.com - April 7 at 12:32 PM

SEC Filings

MEDNAX (NYSE:MD) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

MEDNAX (NYSE:MD) Income Statement, Balance Sheet and Cash Flow Statement

Chart

MEDNAX (NYSE MD) Stock Chart for Thursday, May, 24, 2018

Loading chart…

This page was last updated on 5/24/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.